Weinstein Michael M, Yin Liya, Beigneux Anne P, Davies Brandon S J, Gin Peter, Estrada Kristine, Melford Kristan, Bishop Joseph R, Esko Jeffrey D, Dallinga-Thie Geesje M, Fong Loren G, Bensadoun André, Young Stephen G
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.
J Biol Chem. 2008 Dec 12;283(50):34511-8. doi: 10.1074/jbc.M806067200. Epub 2008 Oct 8.
GPIHBP1-deficient mice (Gpihbp1(-/-)) exhibit severe chylomicronemia. GPIHBP1 is located within capillaries of muscle and adipose tissue, and expression of GPIHBP1 in Chinese hamster ovary cells confers upon those cells the ability to bind lipoprotein lipase (LPL). However, there has been absolutely no evidence that GPIHBP1 actually interacts with LPL in vivo. Heparin is known to release LPL from its in vivo binding sites, allowing it to enter the plasma. After an injection of heparin, we reasoned that LPL bound to GPIHBP1 in capillaries would be released very quickly, and we hypothesized that the kinetics of LPL entry into the plasma would differ in Gpihbp1(-/-) and control mice. Indeed, plasma LPL levels peaked very rapidly (within 1 min) after heparin in control mice. In contrast, plasma LPL levels in Gpihbp1(-/-) mice were much lower 1 min after heparin and increased slowly over 15 min. In keeping with that result, plasma triglycerides fell sharply within 10 min after heparin in wild-type mice, but were negligibly altered in the first 15 min after heparin in Gpihbp1(-/-) mice. Also, an injection of Intralipid released LPL into the plasma of wild-type mice but was ineffective in releasing LPL in Gpihbp1(-/-) mice. The observed differences in LPL release cannot be ascribed to different tissue stores of LPL, as LPL mass levels in tissues were similar in Gpihbp1(-/-) and control mice. The differences in LPL release after intravenous heparin and Intralipid strongly suggest that GPIHBP1 represents an important binding site for LPL in vivo.
GPIHBP1基因缺陷小鼠(Gpihbp1(-/-))表现出严重的乳糜微粒血症。GPIHBP1位于肌肉和脂肪组织的毛细血管内,在中国仓鼠卵巢细胞中GPIHBP1的表达赋予这些细胞结合脂蛋白脂肪酶(LPL)的能力。然而,完全没有证据表明GPIHBP1在体内实际与LPL相互作用。已知肝素可将LPL从其体内结合位点释放出来,使其进入血浆。注射肝素后,我们推断结合在毛细血管中GPIHBP1上的LPL会很快被释放出来,并且我们推测LPL进入血浆的动力学在Gpihbp1(-/-)小鼠和对照小鼠中会有所不同。事实上,对照小鼠注射肝素后血浆LPL水平在1分钟内迅速达到峰值。相比之下,Gpihbp1(-/-)小鼠注射肝素1分钟后血浆LPL水平要低得多,并在15分钟内缓慢升高。与该结果一致的是,野生型小鼠注射肝素后10分钟内血浆甘油三酯急剧下降,但Gpihbp1(-/-)小鼠注射肝素后的前15分钟内血浆甘油三酯变化可忽略不计。此外,注射英脱利匹特可将LPL释放到野生型小鼠的血浆中,但对Gpihbp1(-/-)小鼠释放LPL无效。观察到的LPL释放差异不能归因于LPL在不同组织中的储存量不同,因为Gpihbp1(-/-)小鼠和对照小鼠组织中的LPL质量水平相似。静脉注射肝素和英脱利匹特后LPL释放的差异强烈表明GPIHBP1是LPL在体内的一个重要结合位点。